AI could review data sets to assist clinical scientists ...

Lynk Pharmaceuticals Co., Ltd. ('Lynk Pharmaceuticals'), a clinical-stage innovative drug development company focused on ...

"Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

DOR/ISL is currently at the pre-registration stage of development in the US and is expected to launch in this market in 2026, if approved.

Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic diseaseCarmel Nanthakumar, ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...

It’s been a topsy-turvy week for Novo Nordisk, makers of the popular weight loss drugs Ozempic and Wegovy. Fresh off the heels of a disappointing trial for one experimental drug, the company has just ...

"Dosing the first patient in Phase III represents a major milestone for MDR-001 and for AI-enabled drug development," said Zhangming Niu, Founder and Chief Executive Officer of MindRank. "We believe ...

Explore the impact of AI in drug discovery as 2026 promises critical clinical results and industry transformations.